Subgroup and per-protocol analysis of the European trial on isolated systolic hypertension in the elderly

A

2

X

A

Saturday,May 16, AstorBallroom,2:00 PM ThemeI: SympatheticNervousSystem R S H B

R

A

N G

S H

S M l

C

a

a h

f b

u

e t

l

i g h

t

p

d

c

c c

k

a e

m

p

r

( f

s

h

b

b

t

s

b r c

p

t r s

m

r

c s i

d

h p s p

e w ~

c

s

i

s

c

a

c c

a d

L

H

U

R PO

t

s

h

p

l

o d

e

d

p

o c

p

I

a

i b as

p

b

f

p

a

s

r

7

a p

p

m t

a

i r

r t

( s

J

e s s

S

s

A

ac f

r

s

W T

A S

P

T C

A

a

I

T A

e p n

i s

t

(

m h

( d

( t

p

s

p

5y s t

e S

w

p c s

e s

i

(

s a i

h a

m

s p

s

e y

“ h

e n

t m m

K&M@f4~stolic

p

r n

(

e g n

F

n (

t

f

d

availabla for presentation by mid-199S

( f

n

a

b

g

a ( w b

(

m

s s o

t

e

d

m

e a c

r t

( ( t

p a

a

c

a

s m

g

d n e m

p

c b v h

y a

y a (

a

u

a c

r c

p

r c

p t

s

a

h r s

A

h

a t c

d o

a

v

a

( a

c

s c

A

T

i b p

t

RF

( B

w

p C

a

r

s a

r

are already

S E

L

a

S m a b

i

t

1

renal

b

S

H U

c

p

stage

answers

E

v t

c

h

a

t

end

A I

e

a

b

( a

d

partial

P

I

S

S

c

e

5

to

b

for which

T S

U

(

r m

A

predispose

m

Saturday,May16, BroadwayBallroomNorth, 2:00 PM ThemeIII: ClinicalTrials?What’sNewand WhatDoesit Mean? S E H

G S

m

(

f

f

G

D

T

e

t

o

m

e that

n

I n d

h

c

S

O

b

p

m p

S H

m

m

s

H

d

d

w

n

S

r

p

s

Saturday,May 16, BroadwayBallroomNorth, 2:00 PM ThemeIII: ClinicalTrials?What’sNewand WhatDoesit Mean?

a

o

e a

b

C m h

C U

u

these questinns, available,

i

f

h a h

W s

l

2

soon have an answer include: What level of blood pressure should be the god of treatment in patients at risk of ESRD? What dose of ACE inhibitor, or amalngous agent is optimal for rend protection? What cmnbimation of dr”gs with an ACE inhibitor provides optimal protection? Do the Ang II antagonists provide an alternative to ACE inhibition, with greater potemial? Does ganotype predict not only risk of ESRD, bw also the likelihood that a specific class of agent will prove helpful? The next te” yaars should provide answers to

s

v a

S d

c E f c chamml blocking agents suggests differences within the subclasses, and is far less rigornw. Questions that may

c e

M

B F ac

p

a

e (

4 P

O

c

nf renal disease disease (

e

(

k f

a s d p C

c

p

N

nf hypertension is crucial to protection nf renal function in the patient with hypertension. Few i f physicians would argue that

m

p

p

&H

r c

v (

c

H

d

w

1

M

H t

m a

c a e

N W

s

p l

A I

r e i

c c

v h

P

B

w

1

Saturday,May 16, BroadwayBallroomSouth, 2:00PM ThemeII: The ClinicalCourseof RenalDisease in Hypertension R

U E

c e a w n n

BA

4

o a

n